Wyniki wyszukiwania

1

NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT 1A-receptors

100%

Chlopicki S., Kozlovski V. I., Gryglewski R. J.

Journal of Physiology and Pharmacology

|

2002

|

tom 53

|

nr 4,1

Nebivolol is a unique ß1-adrenoceptor antagonist which possesses peripheral vasodilator properties dependent on endothelial NO. Nebivolol-induced release of NO was attributed to its L stereoisomer and to its ability to stimulate endothelial ß2, ß3 adrenoceptors or 5-HT1A receptors. Here, in the isolated guinea pig heart we analysed coronary vasodilator potency of L- and D-nebivolol and a possible role of ß2, ß3 adrenoceptors and 5-HT1A receptors in nebivolol-induced vasodilation. Surprisingly, we found that not only L-nebivolol (3-30x10-6 M) but also D-nebivolol (3-30x10-6 M) induced coronary vasodilation, and both responses were inhibited by L-NAME (10-4 M). In contrast with the stereoisomers of nebivolol, atenolol at the equimolar concentrations did induce slight vasoconstriction. The nonselective ß1/ß2- adrenoceptor antagonist - nadolol (10-5 M), the selective ß3-adrenoceptor antagonist - L 748337 (10-6 M) and the 5 HT1A receptor antagonist - NAN 190 (5 x 10-6 M), none of them inhibited coronary vasodilation induced by D- and L-nebivolol. In summary, in the isolated guinea pig heart both D- and L-nebivolol act as coronary vasodilators. Coronary vasodilation induced by stereoisomers of nebivolol is mediated by endothelium-derived NO and does not depend on ß2, ß3 adrenoceptors or 5 HT1A receptors.

2

The effect of nebivolol on atherogenesis in apoE - knockout mice

84%

Kus K., Gajda M., Pyka-Fosciak G., Toton-Zuranska J., Pawlowska M., Suski M., Niepsuj A., Nowak B., Wolkow P., Olszanecki R., Jawien J., Korbut R.

Journal of Physiology and Pharmacology

|

2009

|

tom 60

|

nr 4

163-165

Nebivolol is a novel beta1-blocker with a nitric oxide (NO) - potentiating, vasodilatory effect that is unique among beta-blockers. It was already shown that nebivolol ameliorates atherosclerosis in cholesterol-fed rabbits. We, therefore, wanted to investigate whether this is the case in the fine experimental model of atherosclerosis: apolipoprotein E (apoE)- knockout mice. Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23±1.8% vs. 14.6±2.1%) and "cross-section" method (63125±8455 µm2 vs. 91416±8357 m2). This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice.

3

Significant deterioration of anti-atherogenic efficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of atherosclerosis in comparison to single (apolipoprotein E) knockout model

84%

Kus K., Wisniewska A., Toton-Zuranska J., Olszanecki R., Jawien J., Korbut R.

Journal of Physiology and Pharmacology

|

2014

|

tom 65

|

nr 6

4

The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin i metabolism in aorta of apoE-knockout mice

84%

Olszanecki R., Suski M., Gebska A., Toton-Zuranska J., Kus K., Madej J., Bujak-Gizycka B., Jawien J., Korbut R.

Journal of Physiology and Pharmacology

|

2013

|

tom 64

|

nr 3

5

Effect of nebivolol treatment on atherosclerotic plaque components in apoE-knockout mice

84%

Pyka-Fosciak G., Jawien J., Gajda M., Jasek E., Litwin J. A.

Journal of Physiology and Pharmacology

|

2013

|

tom 64

|

nr 6

Ograniczanie wyników

5 Journal of Physiology and Pharmacology

4 Jawien J.

3 Korbut R.

3 Kus K.

3 Olszanecki R.

3 Toton-Zuranska J.

2 Gajda M.

2 Pyka-Fosciak G.

2 Suski M.

1 Bujak-Gizycka B.

1 Chlopicki S.

1 Gebska A.

1 Gryglewski R. J.

1 Jasek E.

1 Kozlovski V. I.

1 Litwin J. A.

1 Madej J.

1 Niepsuj A.

1 Nowak B.

1 Pawlowska M.

1 Wisniewska A.

1 Wolkow P.

1 2014

2 2013

1 2009

1 2002

NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT 1A-receptors

The effect of nebivolol on atherogenesis in apoE - knockout mice

Significant deterioration of anti-atherogenic efficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of atherosclerosis in comparison to single (apolipoprotein E) knockout model

The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin i metabolism in aorta of apoE-knockout mice

Effect of nebivolol treatment on atherosclerotic plaque components in apoE-knockout mice